Form 4: Esperion Therapeutics Chief Commercial Officer Sells Shares to Cover Tax Obligations

Esperion Therapeutics' Chief Commercial Officer, Eric Warren, sold 123 shares of common stock at $2.26 per share to satisfy tax obligations related to vested restricted stock units.

Summary

• Eric Warren, Chief Commercial Officer of Esperion Therapeutics, sold 123 shares of common stock on January 17, 2025.
• The sale was executed at a price of $2.26 per share.
• The transaction was conducted to cover tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Warren directly owns 159,998 shares of Esperion Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for a company officer to sell shares to cover tax obligations related to equity compensation. It is a common practice and does not necessarily indicate a change in the company's outlook.

Comparison to Industry Standards

• Sales of shares by company officers to cover tax obligations are a common practice across the industry.
• The number of shares sold and the price are not unusual for this type of transaction.
• Similar transactions are regularly reported by officers of other publicly traded companies.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small sale by an officer for tax purposes.

Key Dates

Keywords

Esperion Therapeutics, Eric Warren, stock sale, Form 4, insider trading, restricted stock units, tax obligations, chief commercial officer